We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

THE BINDING SITE

Engages in the research, development, manufacture, and distribution of immunodiagnostic assays, as wel as specialized... read more Featured Products: More products

Download Mobile App





Binding Site Exhibits Special Protein Analyzer Optilite at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 12 Apr 2022

Binding Site (Birmingham, UK) participated in the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB) hosted by the German Society of Clinical Chemistry and Laboratory Medicine (DGKL), one of the oldest national societies devoted to clinical chemistry and laboratory medicine. More...

At EUROMEDLAB 2022, Binding Site exhibited its special protein analyzer, Optilite which is the perfect solution for the modern protein laboratory. Integrating powerful technology and intelligent software, Optilite is fully optimized for protein analysis to create simplicity from complex analytical processes. The true benchtop analyzer and assays work in perfect harmony, giving labs complete peace of mind and the freedom to allocate their time more effectively.

Optilite is specifically designed for laboratory workflow optimization. Its continuous loading of samples, reagents, and consumables plus automatic re-dilution to end result enable labs to maximize test throughput while minimizing hands-on time. A comprehensive menu of special protein assays, including Binding Site’s Freelite test, is available. With a compact benchtop design, Optilite is quick to install, easy to maintain, and is equipped with full LIS connectivity and automatic barcode recognition for full traceability. Unique to Optilite is a robust antigen excess protection system with three detection methods, thereby ensuring accurate and reliable results.

Related Links:
Binding Site 


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.